Multi-racial cytokine profiling reveals immune dysregulation, not chronic inflammation, in polycystic ovary syndrome
Data files
Jan 05, 2026 version files 50.60 KB
-
README.md
3.93 KB
-
Supplemental_File_1.xlsx
46.68 KB
Abstract
This dataset contains plasma concentrations of 96 immune-related proteins measured using a custom Luminex xMAP assay in 40 women (20 with PCOS, 20 controls) matched for age, BMI, and race (Black and White). The comprehensive panel includes:
Growth Factors (12): EGF, FGF-2, FLT3L, G-CSF, GM-CSF, M-CSF, PDGF-AA, PDGF-AB, SCF, TGF-α, TPO, and VEGF-A
Cytokines (35): APRIL, BAFF, IFN-α2, IFN-β, IFN-γ, IFN-ω, IL-1α, IL-1β, IL-1Rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, IL-12p40, IL12-p70, IL-13, IL-15, IL-16, IL-17A, IL-17E, IL-17F, IL-18, IL-20, IL-21, IL-22, IL-23, IL-24, IL-27, IL-28A, IL-29, IL-31, IL-33, IL-34, IL-35, LIF, TNF-α, TNF-β, and TSLP
Chemokines (41): Including 6CKINE, BCA1, CCL28, CTACK, CXCL16, ENA78, EOTAXIN variants, FRACTALKINE, GCP2, GRO-α, IP-10, MCP variants, MIP variants, RANTES, and others
Other Immune-Related Proteins (8): CD137, CD40L, Granzyme A, Granzyme B, Perforin, sFAS, sFASL, and TRAIL
Dataset DOI: 10.5061/dryad.ttdz08m9t
Description of the data and file structure
Study Participants and Cohort Design Samples were obtained from a prospective study of over 2500 women and adolescents (aged ≥14 years) presenting for evaluation of androgen excess at reproductive endocrinology clinics. PCOS was defined using the 1990 National Institutes of Health (NIH) criteria. For this analysis, we performed a cross-sectional case-control study with a subsampled cohort of 40 women: 20 with PCOS and 20 controls, matched for race (10 White, 10 Black in each group), age, and BMI. Fasting blood samples were obtained during the follicular phase (cycle days 3-8), and plasma was separated and cryopreserved.
Luminex Assay Plasma samples (10 μL) were analyzed using blinded Xmap Intelliflex Luminex assays. CRP was measured at 1:40,000 dilution, while 96 cytokines were measured without dilution using comprehensive custom immune protein panels: Human Cytokine/Chemokine/Growth Factor panel A (Cat# HCYTA-60K-PXBK48) and panel B (Cat# HCYTB-60K-PXBK48), and Human Cardiovascular Disease panel for CRP (Cat# HCVD3MAG-67K) (Millipore). Standard curves were generated, and concentrations interpolated using Belysa Immunoassay Curve Fitting software.
Files and variables
File: Supplemental_File_1.xlsx
Description: Concentrations of 96 cytokines. All variable abbreviations and units are indicated in the key tab. Missing or undetectable values are indicated by "-".
Variables
- Control/PCOS
- Age
- Black/White
- BMI
- SCD40L
- EGF
- EOTAXIN
- FGF2
- FLT3L
- FRACTALKINE
- GCSF
- GMCSF
- GROA
- IFNA2
- IFNY
- IL1A
- IL1B
- IL1RA
- IL2
- IL3
- IL4
- IL5
- IL6
- IL7
- IL8
- IL9
- IL10
- IL12P40
- IL12P70
- IL13
- IL15
- I17A
- IL17E
- IL17F
- IL18
- IL22
- IL27
- IP10
- MCP1
- MCP3
- MCSF
- MDC
- MIGCXL9
- MIP1A
- MIP1B
- PDGFAA
- PDGFAB
- RANTES
- TGFA
- TNFA
- TNFB
- VEGFA
- 6CKINE
- BCA1
- SFAS
- SFASL
- SCD137
- APRIL
- BAFF
- IL16
- CCL28
- CTACK
- CXCL16
- ENA17A
- GRANZYMEA
- EOTAXIN2
- EOTAXIN3
- IL35
- GCP2
- HNGB1
- I309
- GRANZYMEB
- IFNB
- IFNW
- IL11
- IL23
- IL20
- IL24
- IL28A
- IL31
- IL29
- IL33
- IL21
- IL34
- LIF
- LIMPHOTACTIN
- MCP2
- MCP4
- MIP1Y
- MIP3A
- ITAC
- MIP3B
- MPIF1
- SCF
- CDF1
- TARC
- TPO
- TRAIL
- TSLP
- PERFORIN
Software
This is an .xlsx file. Read with Microsoft Excel.
Access information
N/A
Human subjects data
This dataset contains completely de-identified human subjects data that complies with Dryad's standards for public domain publication. The original study was conducted under institutional review board approval at the University of Alabama at Birmingham and Cedars-Sinai Medical Center between 1987 and 2010. Written informed consent was obtained from all participants, including explicit consent for future research use of biological samples and associated de-identified data.
The dataset has been thoroughly de-identified and contains only the following variables: cytokine concentrations (96 analytes), self-reported race (White/Black), PCOS diagnosis status, BMI, and age. All direct identifiers have been removed, including participant codes, dates, geographic identifiers, and any other information that could potentially identify individual participants. No linking codes or keys exist that could re-identify participants.
The de-identification process ensures compliance with applicable privacy regulations and ethical guidelines for human subjects research. The data represents aggregate measurements suitable for scientific analysis while protecting participant privacy. All participants provided informed consent for the use of their biological samples and associated clinical data for research purposes, including publication of de-identified results.
Study Participants and Cohort Design Samples were obtained from a prospective study of over 2500 women and adolescents (aged ≥14 years) presenting for evaluation of androgen excess at reproductive endocrinology clinics. PCOS was defined using the 1990 National Institutes of Health (NIH) criteria. For this analysis, we performed a cross-sectional case-control study with a subsampled cohort of 40 women: 20 with PCOS and 20 controls, matched for race (10 White, 10 Black in each group), age, and BMI. Fasting blood samples were obtained during the follicular phase (cycle days 3-8), and plasma was separated and cryopreserved.
Luminex Assay Plasma samples (10 μL) were analyzed using blinded Xmap Intelliflex Luminex assays. CRP was measured at 1:40,000 dilution, while 96 cytokines were measured without dilution using comprehensive custom immune protein panels: Human Cytokine/Chemokine/Growth Factor panel A (Cat# HCYTA-60K-PXBK48) and panel B (Cat# HCYTB-60K-PXBK48), and Human Cardiovascular Disease panel for CRP (Cat# HCVD3MAG-67K) (Millipore). Standard curves were generated, and concentrations interpolated using Belysa Immunoassay Curve Fitting software.